Alexion Pharmaceuticals Рентабельность активов
Что обозначает Рентабельность активов в Alexion Pharmaceuticals?
Рентабельность активов Alexion Pharmaceuticals Inc. является 10.08%
Какое определение для Рентабельность активов?
Рентабельность активов показывает, насколько прибыльными являются активы компании для получения дохода. Она рассчитывается путем деления чистого дохода на среднюю общую сумму активов.
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Рентабельность активов компаний в Health Care сектор на NASDAQ по сравнению с Alexion Pharmaceuticals
Что делает Alexion Pharmaceuticals?
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Компании с рентабельность активов похож на Alexion Pharmaceuticals
- Tech Mahindra имеет Рентабельность активов из 10.07%
- A.G. BARR p.l.c имеет Рентабельность активов из 10.07%
- Academy Sports & Outdoors имеет Рентабельность активов из 10.07%
- Beekay Steel Industries имеет Рентабельность активов из 10.08%
- Motorsport Gaming US имеет Рентабельность активов из 10.08%
- bioMérieux SA имеет Рентабельность активов из 10.08%
- Alexion Pharmaceuticals имеет Рентабельность активов из 10.08%
- Cairn Homes plc имеет Рентабельность активов из 10.09%
- Canadian Natural Resources имеет Рентабельность активов из 10.09%
- IMI Plc имеет Рентабельность активов из 10.09%
- STEICO SE имеет Рентабельность активов из 10.10%
- Steico Se имеет Рентабельность активов из 10.10%
- Seamec имеет Рентабельность активов из 10.10%